Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II study of ALLN-177 in adolescents and adults with primary hyperoxaluria or severe forms of secondary hyperoxaluria

Next Previous
Trial Profile

A phase II study of ALLN-177 in adolescents and adults with primary hyperoxaluria or severe forms of secondary hyperoxaluria

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Reloxaliase (Primary)
  • Indications Hyperoxaluria; Primary hyperoxaluria
  • Focus Therapeutic Use
  • Acronyms Study 206
  • Sponsors Allena Pharmaceuticals

    • Most Recent Events

    • 13 Nov 2019 According to an Allena Pharmaceuticals media release, company plans to meet with regulatory agencies in the first quarter of 2020 to discuss the registrational path for reloxaliase in high-risk EH patients with CKD.
    • 13 Nov 2019 According to an Allena Pharmaceuticals media release, data were presented at the American Society of Nephrology Kidney Week 2019.
    • 07 Nov 2019 According to an Allena Pharmaceuticals media release, data from the study will be presented at the American Society of Nephrology Kidney Week 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top